Zydus Lifesciences and its U.S. unit will pay $120 million to Astellas Pharma to settle a patent dispute over the bladder disorder drug Mirabegron. They will also pay a pre-paid per-unit licensing fee on sales of their generic Mirabegron in the U.S. until September 2027.

The deal allows Zydus to continue marketing its generic Mirabegron in the United States. Other terms and conditions of the agreement are confidential. Shares of Zydus rose 1.3% after the announcement.

This settlement follows Lupin’s decision to settle a similar dispute with Astellas for $90 million. Analysts believe this could delay the entry of other generic rivals into the U.S. market, giving Zydus and Lupin a period of limited competition.

Read more at Yahoo Finance: India’s Zydus Life agrees $120 million settlement with Astellas over bladder drug